BTK (Bruton Tyrosine Kinase) is a non-receptor tyrosine kinase that belongs to the TEC kinase family. It is primarily involved in B-cell receptor (BCR) signaling pathways and plays a critical role in regulating B-cell differentiation, survival, and development. BTK mutations or aberrant activation are closely associated with various immune disorders and B-cell-related cancers, making BTK an important therapeutic target for many diseases.
Ba/F3 cells are a cell line derived from murine IL-3-dependent pre-B cells that require interleukin-3 (IL-3) for survival and proliferation. When wild-type or mutant BTK genes are introduced, these cells become independent of IL-3 and start proliferating via BTK-mediated signaling pathways. As such, BTK Ba/F3 cells serve as a classical tool for validating the functional activity of BTK mutations, analyzing signaling pathways, and screening and evaluating the efficacy of BTK inhibitors. This is particularly relevant for testing resistance-related mutations, such as C481S.
Genomeditech provides Ba/F3 cell lines targeting BTK and other related genes to support BTK inhibitor screening, activity validation, and in vitro efficacy studies.
